The TB Alliance will be participating in the partnering session of BIO's Annual Convention, June 22-25 in Washington, DC.
We look forward to meeting companies with promising new agents for the treatment of tuberculosis, or interested in participating in drug development.
The focus of the TB Alliance is on compounds that have demonstrated clear evidence of significant and improved anti-TB activity, and/or that may become lead compounds in the treatment of TB. Priority is given to agents with the potential to shorten the duration of chemotherapy, improve the treatment of latent TB, and be effective against MDR-TB.